Resistance Exercise Training For Radically Treated Respiratory Cancer
- Conditions
- Respiratory Cancer
- Interventions
- Other: Conventional resistance trainingOther: Whole body vibration resistance training
- Registration Number
- NCT00752700
- Lead Sponsor
- University Hospital, Ghent
- Brief Summary
The first part of the study is an observational part. In eligible patients with early stage respiratory cancer, the primary and secondary endpoints will be evaluated before and after their scheduled radical cancer therapy. The measured variables, include a blood sample, pulmonary function tests, level of dyspnea, exercise tests, measurement of body composition, respiratory and peripheral muscle force, health related quality of life and psychological status. Only registered participants having completed a radical treatment and having either less than 70% of the predicted normal value of the quadriceps force (QF) or a decrease of more than 10% predicted value of the QF between pre-and post radical treatment, will be allowed to participate to the second part of the study. These patients will then be randomized in three groups. Group A, the control group, will have the usual care and follow up according to clinical symptoms. Group B will be offered a conventional resistance training program (CRT), and group C, will be offered a whole body vibration resistance training (WBV) on the FITVIBE-platform. All previous variables will be measured after 6 and 12 weeks of training.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 113
-
Patients with non-small cell or small cell lung cancer or mesothelioma candidate for radical treatment
- either by surgical resection with or without perioperative chemotherapy
- or by thoracic radiotherapy with or without chemotherapy
-
Between 18 and 80 years of age
-
Written informed consent
Supplementary criteria for PART II:
-
Treatment for their cancer considered radical
- either by surgical resection with or without perioperative chemotherapy
- or by thoracic radiotherapy with or without chemotherapy
-
having less than 70% of the predicted normal value of the Quadriceps Force (QF) or a decrease of more than 10% predicted value of the QF between the baseline and post-radical therapy measurement of QF
-
Post treatment assessment maximum 14 days after radical treatment or between 6th and 8th week after radical treatment if the latter consists only of surgical resection
Patients presenting with one or more of the following will be excluded:
- Severe anemia (Hb below 8 g/dl)
- Fever (> 38°C)
- Cachexia (loss of more than 35% of premorbid weight)
- Severe cardiac, neurological and orthopedic co-morbidity interfering with exercise training.
- A pacemaker, hip, knee of shoulder prosthesis or recently introduced spirals, metal pens, bolts or plates
- Uncontrolled diabetes, epilepsy or migraine
- Uncontrolled vertebral diseases (osteoporotic or metastatic fractures, acute hernia, discopathy, spondylitis)
- Open wounds
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description 2 Conventional resistance training Conventional resistance training program (CRT) 3 Whole body vibration resistance training Whole body vibration resistance training (WBV) on the FITVIBE-platform
- Primary Outcome Measures
Name Time Method The change of 6MWD observed between pre-and post radical treatment 12 weeks between post radical treatment and after a 12 week resistance training 12 weeks
- Secondary Outcome Measures
Name Time Method Body composition 12 weeks Maximal exercise capacity 12 weeks The changes of the following variables: Muscle strength 12 weeks Muscle mass 12 weeks Muscle force 12 weeks Quality of life 12 weeks Anxiety and depression scores 12 weeks Dyspnea scores 12 weeks 6MWD 12 weeks
Trial Locations
- Locations (4)
AZ St. Jan
🇧🇪Brugge, Belgium
CHU Sart Tilman
🇧🇪Liège, Belgium
CHU Saint Pierre
🇧🇪Brussel, Belgium
University Hospital Ghent
🇧🇪Ghent, Belgium